There have been marked improvements in treatment options but none have yet been shown to induce remission
The past decade has seen major advances in the diagnosis and management of ankylosing spondylitis (AS) and in research into its pathogenesis. It remains the case that no current treatments have been shown to lead to disease remissions or to halt the progression of the bony ankylosis that causes the major morbidity associated with this condition. Nonetheless, improved diagnostic methods and management have led to major benefits for patients, with marked improvements in quality of life with reduced treatment-associated side effects.
- 1. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361-368.
- 2. Reed MD, Dharmage S, Boers A, et al. Ankylosing spondylitis: an Australian experience. Intern Med J 2008; 38: 321-327.
- 3. Rudwaleit M, Landewe R, van der Heijde D, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis 2009; 68: 770-776.
- 4. Mau W, Zeidler H, Mau R, et al. Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year followup. J Rheumatol 1988; 15:1109-1114.
- 5. Sieper J, Rudwaleit M, Lenaerts J, et al. Partial remission in ankylosing spondylitis and non-radiographic axial spondyloarthritis in treatment with infliximab plus naproxen or naproxen alone: associations between partial remission and baseline disease characteristics. Rheumatology (Oxford) 2016; 55: 1946-1953.
- 6. Millner JR, Barron JS, Beinke KM, et al. Exercise for ankylosing spondylitis: an evidence-based consensus statement. Semin Arthritis Rheum 2016; 45: 411-427.
- 7. O’Dwyer T, McGowan E, O’Shea F, Wilson F. Physical activity and exercise: perspectives of adults with ankylosing spondylitis. J Phys Act Health 2016; 13: 504-513.
- 8. Arturi P, Schneeberger EE, Sommerfleck F, et al. Adherence to treatment in patients with ankylosing spondylitis. Clin Rheumatol 2013; 32: 1007-1015.
- 9. Van Rossen L, Withrington RH. Improving the standard of care for people with ankylosing spondylitis and a new approach to developing specialist ESP-Led AS clinics. Musculoskeletal Care 2012; 10: 171-177.
- 10. van Eijk-Hustings Y, van Tubergen A, Bostrom C, et al. EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis. Ann Rheum Dis 2012; 71: 13-19.
- 11. Lesko M, Young M, Higham R. Managing inflammatory arthritides: role of the nurse practitioner and physician assistant. J Am Acad Nurse Pract 2010; 22: 382-392.
- 12. El Miedany Y, Youssef S, Ahmed I, El Gaafary M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol 2006; 101: 311-317.
- 13. Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol 2016; 68: 282-298.
- 14. Robinson PC, Bird P, Lim I, et al. Consensus statement on the investigation and management of non-radiographic axial spondyloarthritis (nr-axSpA). Int J Rheum Dis 2014; 17: 548-556.
- 15. Braun J, Pavelka K, Ramos-Remus C, et al. Clinical efficacy of etanercept versus sulfasalazine in ankylosing spondylitis subjects with peripheral joint involvement. J Rheumatol 2012; 39: 836-840.
- 16. Benitez-Del-Castillo JM, Garcia-Sanchez J, Iradier T, Banares A. Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye (Lond) 2000; 14 (Pt 3A): 340-343.
- 17. Sieper J, van der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis 2013; 72: 815-822.
- 18. Robinson PC, Brown MA. The window of opportunity: a relevant concept for axial spondyloarthritis. Arthritis Res Ther 2014; 16: 109.
- 19. van der Heijde D, Salonen D, Weissman BN, et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 2009; 11: R127.
- 20. Haroon N, Inman RD, Learch TJ, et al. The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 2013; 65: 2645-2654.
- 21. Wellcome Trust Case Control Consortium, Australo-Anglo-American Spondylitis Consortium, Burton PR, et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 2007; 39: 1329-1337.
- 22. Sieper J, Deodhar A, Marzo-Ortega H, et al. Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. Ann Rheum Dis 2016. doi:10.1136/annrheumdis-2016-210023
- 23. Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015; 386: 541-551.
- 24. Robinson PC. The genetics of ankylosing spondylitis and anterior uveitis [PhD thesis]. Brisbane: University of Queensland, 2014.
- 25. Fabiani C, Vitale A, Lopalco G, et al. Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis: state of the art. Clin Rheumatol 2016; 35: 2631-2638.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.